Baird lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $37.00 (from $40.00) while maintaining a Outperform rating. Coherus ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Coherus Biosciences (CHRS) PT Lowered to $24 at Credit Suisse; Neulasta Biosimilar CRL Poses Greater Risk for CHS-1701June 14, 2017 9:10 AM Coherus Biosciences (CHRS) Neulasta Biosimilar Delay 'Appears Resolvable' - CowenJune 12, 2017 12:29 PM Coherus Biosciences (CHRS) PT Lowered to $43 at BMO Capital; 'CHS-1701 CRL Disappointing but Issues Addressable - Buy on Weakness' June 12, 2017 12:03 PM Pre-Open Movers 06/12: (TROV) (GTXI) (GE) Higher; (CHRS) (AMD) (AAPL) Lower (more...)June 12, 2017 9:31 AM Wall St. falls as Apple drags tech shares lowerJune 12, 2017 7:40 AM Coherus BioSciences (CHRS) Receives CRL from FDA for CHS-1701 BLAJune 12, 2017 6:38 AM Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)June 12, 2017 6:37 AM